Tag: Tirzepatide
New weight loss drug reduces AHI in certain patients
April 17, 2024HME News Staff
INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events...
Sleep Apnea, Tirzepatide, weight loss drugs
Sponsored Stories
How Advanced Diabetes Supply is Driving Value-Based Health Outcomes
By Advanced Diabetes SupplySOS Achieves Remarkable 400% Growth in 2023, Bolsters Team with Director Appointment
By Strategic Office SupportCyber Siege: The Financial Vulnerability Healthcare Didn't See Coming
By Strategic Office SupportA new staffing model that delivers ready-to-work pros, boosting efficiency and lowering costs.
By Tactical Back Office